Abstract：
Antiplatelet agents, particularly P2Y12 receptor inhibitors, are critical medicines in the prevention and treatment of thrombotic diseases in the clinic. However, their long-term use introduces a significant risk of bleeding in patients with cardiovascular diseases. Whether the bleeding is caused by the drug itself or due to surgical procedures or trauma, the need to rapidly reverse the effects of antiplatelet agents in the circulation is essential; however, no such agents are currently available. To address this need, here we describe a strategy that uses cell-membrane-wrapped nanoparticles (CM-NPs) for the rapid reversal of P2Y12 inhibitors. CM-NPs are fabricated with membranes derived from 293T cells genetically engineered to overexpress the P2Y12 receptor. Our findings support the potential of CM-NPs as a strategy for managing bleeding complications associated with P2Y12 receptor inhibitors, offering an approach to improve the safety in the use of these drugs in clinical settings.
摘要：
抗血小板药,特别是P2Y12受体抑制剂，是临床上预防和治疗血栓性疾病的关键药物。然而,长期使用它们会给心血管疾病患者带来严重的出血风险。无论出血是由药物本身引起的，还是由于外科手术或外伤引起的，需要迅速逆转抗血小板药物在循环中的作用是必不可少的;然而,目前没有这样的代理。为了满足这一需求，在这里,我们描述了一种使用细胞膜包裹纳米颗粒(CM-NP)快速逆转P2Y12抑制剂的策略.CM-NP是用衍生自293T细胞的膜制造的,所述膜被基因工程化以过表达P2Y12受体。我们的研究结果支持CM-NP作为治疗与P2Y12受体抑制剂相关的出血并发症的策略的潜力。提供了一种方法来提高这些药物在临床环境中使用的安全性。
